



---

**TTK Healthcare**  
**LIMITED**

---

TTKH:SECL:GJ:152:17

August 04, 2017

National Stock Exchange of India Limited (NSE)  
Exchange Plaza  
Bandra Kurla Complex  
Bandra East  
Mumbai 400 051

---

Scrip Code : TTKHLCARE

---

Dear Sirs,

**Re : Unaudited Financial Results for the First Quarter ended 30<sup>th</sup> June, 2017**

We are forwarding herewith the Unaudited Financial Results for the First Quarter ended 30<sup>th</sup> June, 2017, approved by the Board of Directors of the Company at their Meeting held today.

Kindly take the above document on record.

Thanking you

Yours faithfully  
**For TTK Healthcare Limited**

**(S KALYANARAMAN)**  
*Director & Wholetime Secretary*

Encl. : a/a



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017 (STANDALONE)

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

S. No.	Particulars	For the Quarter ended			(Rs. in lakhs)
		(30/06/2017)	(30/06/2016)	(31/03/2017)	For the Year ended
		Unaudited	Unaudited	Unaudited	Unaudited
I.	Revenue from Operations	12,536.58	15,272.43	11,671.82	52,780.55
II.	Other Income	119.50	126.75	173.44	572.75
III.	<b>Total Income (I + II)</b>	<b>12,656.08</b>	<b>15,399.18</b>	<b>11,845.26</b>	<b>53,353.30</b>
IV.	Expenses				
	(a) Cost of materials consumed	1,203.34	1,178.74	1,288.03	4,681.37
	(b) Purchase of Stock-in-trade	5,116.64	5,441.69	4,316.67	19,750.01
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	(456.34)	167.41	160.43	(87.42)
	(d) Employee benefits expense	2,400.90	2,279.75	2,082.52	8,669.33
	(e) Finance Costs	68.83	102.02	59.94	311.49
	(f) Depreciation and Amortization Expense	297.59	294.65	294.50	1,191.59
	(g) Other Expenses	4,472.71	5,029.02	2,786.77	15,789.04
	<b>Total Expenses (IV)</b>	<b>13,103.67</b>	<b>14,493.28</b>	<b>10,988.86</b>	<b>50,305.41</b>
V.	<b>Profit / (Loss) before Exceptional and Tax (III - IV)</b>	<b>(447.59)</b>	<b>905.90</b>	<b>856.40</b>	<b>3,047.89</b>
VI.	Exceptional Items	-	-	-	-
VII.	<b>Profit / (Loss) before Tax (V - VI)</b>	<b>(447.59)</b>	<b>905.90</b>	<b>856.40</b>	<b>3,047.89</b>
VIII.	Tax Expense:				
	(1) Current Tax	-	308.00	250.00	982.00
	(2) Deferred Tax	-	38.66	(30.29)	57.83
IX.	<b>Profit / (Loss) for the period from Continuing Operations (VII-VIII)</b>	<b>(447.59)</b>	<b>559.24</b>	<b>636.69</b>	<b>2,008.06</b>
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-
XI.	Tax Expense of Discontinued Operations	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	-	-	-
XIII.	<b>Profit / (Loss) for the period (IX + XII)</b>	<b>(447.59)</b>	<b>559.24</b>	<b>636.69</b>	<b>2,008.06</b>
XIV.	Other Comprehensive Income:				
	(A) (i) Items that will not be reclassified to profit or loss	108.51	57.38	(119.25)	88.95
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	(B) (i) Items that will be reclassified to profit or loss	-	18.30	-	(23.30)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	(6.33)	-	8.06
XV.	<b>Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]</b>	<b>(339.08)</b>	<b>628.59</b>	<b>517.44</b>	<b>2,081.77</b>
	Paid-up Equity Share Capital (Face Value Rs.10 per share)	776.60	776.60	776.60	776.60
	Reserve as per Balance Sheet of previous accounting year	-	-	-	14,970.46

<b>XVI. Earnings per Equity Share (For Continuing Operations):</b>				
(1) Basic	(5.76)	7.20	8.20	25.86
(2) Diluted	(5.76)	7.20	8.20	25.86
<b>XVII. Earnings per Equity Share (For Discontinued Operation):</b>				
(1) Basic	-	-	-	-
(2) Diluted	-	-	-	-
<b>XVIII. Earnings per Equity Share (For Discontinued and Continuing Operation):</b>				
(1) Basic	(5.76)	7.20	8.20	25.86
(2) Diluted	(5.76)	7.20	8.20	25.86

**Notes:**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 4th August, 2017 at Chennai.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Company has adopted Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, from 1st April, 2017. The date of transition to Ind AS is 1st April, 2016 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India. The impact of transition has been accounted for in the opening reserves and the comparative period figures have been reinstated accordingly.
- The financial results for the Quarters ended 30th June, 2016 and 31st March, 2017 and the Year ended 31st March, 2017 have not been audited and reviewed and have been presented based on the information compiled by the Management after making the necessary adjustments to give a true and fair view of the results, in accordance with Ind AS.
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's presentation.
- This Statement is also available on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) and also on the website of the Company ([www.ttkhealthcare.com](http://www.ttkhealthcare.com)).
- Reconciliation between previously reported (referred to as "Previous GAAP") and Ind AS:

(Rs. in lakhs)

Nature of adjustments		3 months ended	3 months ended	Year ended
		(30/06/2016)	(31/03/2017)	(31/03/2017)
<b>Net Profit under Previous GAAP</b>		<b>560.49</b>	<b>558.24</b>	<b>1,933.37</b>
Actuarial loss on employee defined benefit funds recognized in Other Comprehensive		-	141.52	141.52
Expected Credit losses - Damaged Inventories provision		-	(91.34)	(91.34)
Expected Credit losses - Provision for doubtful trade receivables		-	(3.18)	(3.18)
Reversal of depreciation credited from Reserve and Surplus		(1.25)	(1.26)	(5.02)
Deferred Tax Assets		-	32.71	32.71
<b>Sub-Total</b>		<b>559.24</b>	<b>636.69</b>	<b>2,008.06</b>
<b>Other Comprehensive Income:</b>				
(A)	(i) Items that will not be reclassified subsequently to Profit or Loss:			
	(a) Remeasurements of the defined benefit plans	-	(141.52)	(141.52)
	(b) Equity Instruments through other comprehensive income	57.38	22.27	230.47
	<b>Sub-Total</b>	<b>57.38</b>	<b>(119.25)</b>	<b>88.95</b>
(B)	(i) Items that may be reclassified subsequently to Profit or Loss:			
	(a) Debt instruments through other comprehensive income	18.30	-	(23.30)
	(b) Income tax relating to items that may be reclassified to Profit or Loss	(6.33)	-	8.06
	<b>Sub-Total</b>	<b>11.97</b>	<b>-</b>	<b>(15.24)</b>
<b>Total Comprehensive Income for the period</b>		<b>628.59</b>	<b>517.44</b>	<b>2,081.77</b>

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN  
EXECUTIVE VICE CHAIRMAN

Place: Chennai  
Date: August 04, 2017





# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com


## SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER ENDED 30th JUNE, 2017

S. No.	Particulars	For the Quarter ended			(Rs. in lakhs)
		(30/06/2017)	(30/06/2016)	(31/03/2017)	For the Year ended
		Unaudited	Unaudited	Unaudited	Unaudited
1.	<b>Segment Revenue:</b> <b>(Sales and Other Operating Income)</b>				
	(a) Pharmaceuticals	3,520.43	5,187.16	3,927.12	19,015.79
	(b) Medical Devices	746.42	685.57	681.33	2,561.75
	(c) Consumer Products	6,460.31	7,412.65	4,990.00	23,950.51
	(d) Foods	1,783.41	1,959.42	2,055.78	7,174.86
	(e) Others	26.01	27.63	17.59	77.64
	<b>Total</b>	<b>12,536.58</b>	<b>15,272.43</b>	<b>11,671.82</b>	<b>52,780.55</b>
	<b>Less : Inter Segment Revenue</b>	-	-	-	-
	<b>Net Sales / Income from Operations</b>	<b>12,536.58</b>	<b>15,272.43</b>	<b>11,671.82</b>	<b>52,780.55</b>
2.	<b>Segment Results:</b> <b>[Profit (+) / Loss (-) before tax and interest from each segment]</b>				
	(a) Pharmaceuticals	(358.33)	318.93	220.58	1,318.48
	(b) Medical Devices	151.65	102.25	215.23	528.86
	(c) Consumer Products	270.28	725.14	688.62	2,502.06
	(d) Foods	(196.05)	81.41	(33.25)	(242.25)
	(e) Others	8.42	11.64	7.90	29.47
	<b>Total</b>	<b>(124.03)</b>	<b>1,239.37</b>	<b>1,099.08</b>	<b>4,136.62</b>
	<b>Less : Finance Cost</b>	68.83	102.02	59.94	311.49
	<b>Less : Unallocable Expenses (Net of Unallocable Income)</b>	254.73	231.45	182.74	777.24
	<b>Total Profit (+) / Loss (-) before tax</b>	<b>(447.59)</b>	<b>905.90</b>	<b>856.40</b>	<b>3,047.89</b>
		<b>As on</b>	<b>As on</b>	<b>As on</b>	<b>As on</b>
		<b>30/06/2017</b>	<b>30/06/2016</b>	<b>31/03/2017</b>	<b>31/03/2017</b>
3.	<b>Segment Assets</b>				
	(a) Pharmaceuticals	3,565.32	5,435.64	3,960.88	3,960.88
	(b) Medical Devices	2,701.55	2,469.12	2,588.53	2,588.53
	(c) Consumer Products	3,948.02	5,109.75	3,541.67	3,541.67
	(d) Foods	10,167.93	10,781.47	10,351.46	10,351.46
	(e) Others	80.24	78.36	77.80	77.80
	<b>Total</b>	<b>20,463.06</b>	<b>23,874.34</b>	<b>20,520.34</b>	<b>20,520.34</b>
	<b>Unallocated</b>	11,541.63	12,993.40	10,911.29	10,911.29
	<b>Total Assets</b>	<b>32,004.69</b>	<b>36,867.74</b>	<b>31,431.63</b>	<b>31,431.63</b>
4.	<b>Segment Liabilities</b>				
	(a) Pharmaceuticals	3,901.15	4,482.83	3,112.06	3,112.06
	(b) Medical Devices	899.31	953.89	857.62	857.62
	(c) Consumer Products	5,343.93	6,369.56	5,278.04	5,278.04
	(d) Foods	970.12	1,119.99	871.79	871.79
	(e) Others	135.57	120.57	126.76	126.76
	<b>Total</b>	<b>11,250.08</b>	<b>13,046.84</b>	<b>10,246.27</b>	<b>10,246.27</b>
	<b>Unallocated</b>	3,879.92	5,895.74	3,879.92	3,879.92
	<b>Total Liabilities</b>	<b>15,130.00</b>	<b>18,942.58</b>	<b>14,126.19</b>	<b>14,126.19</b>

**Notes:**

1. Segments have been identified in line with the Accounting Standard on Segment Reporting (AS-17) considering the organisation structure and the differential risks and returns of these segments.
2. Details of products included in each of the Segments are as below :
  - ❖ Pharmaceuticals include products for both Human and Veterinary use.
  - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
  - ❖ Consumer Products comprise of marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc., (Own Brands) and also trading of Branded Condoms.
  - ❖ Foods comprise of manufacturing and marketing of Food Products.
  - ❖ "Others" include Printing and Publishing of Maps and Atlases.
3. The Company has reclassified distribution of Woodward's Gripewater as part of Consumer Products Segment which was previously reported under Pharmaceuticals. The changes have been made retrospectively to the segment information of prior periods.
4. The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
5. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

  
T T RAGHUNATHAN  
EXECUTIVE VICE CHAIRMAN

Place: Chennai  
Date: August 04, 2017



# TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086  
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017 (STANDALONE)

Sl. No.	Particulars	(Rs. in lakhs)			
		For the Quarter ended			For the Year ended
		(30/06/2017)	(30/06/2016)	(31/03/2017)	(31/03/2017)
		Unaudited	Unaudited	Unaudited	Unaudited
1.	Total income from Operations	12,536.58	15,272.43	11,671.82	52,780.55
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	(447.59)	905.90	856.40	3,047.89
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)	(447.59)	905.90	856.40	3,047.89
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	(447.59)	559.24	636.69	2,008.06
5.	Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	(339.08)	628.59	517.44	2,081.77
6.	Equity Share Capital (Face Value of Rs.10/- per share)	776.60	776.60	776.60	776.60
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year				14,970.46
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)				
	(a) Basic	(5.76)	7.20	8.20	25.86
	(b) Diluted	(5.76)	7.20	8.20	25.86

### Notes:

- The above is an extract of the detailed Statement of Unaudited Financial Results for the First Quarter ended 30th June, 2017, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The full financial results for the First Quarter ended 30th June, 2017 are available on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- These financial results have been reviewed by the Audit Committee of the Company and approved by the Board of Directors at their Meeting held on 4th August, 2017.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The financial results for the Quarters ended 30th June, 2016 and 31st March, 2017 and the Year ended 31st March, 2017 have not been audited and reviewed and have been presented based on the information compiled by the Management after making the necessary adjustments to give a true and fair view of the results, in accordance with Ind AS.
- Reconciliation between previously reported (referred to as "Previous GAAP") and Ind AS:

Nature of adjustments		(Rs. in lakhs)		
		3 months ended	3 months ended	Year ended
		(30/06/2016)	(31/03/2017)	(31/03/2017)
<b>Net Profit under Previous GAAP</b>		<b>560.49</b>	<b>558.24</b>	<b>1,933.37</b>
Actuarial loss on employee defined benefit funds recognized in Other Comprehensive		-	141.52	141.52
Expected Credit losses - Damaged Inventories provision		-	(91.34)	(91.34)
Expected Credit losses - Provision for doubtful trade receivables		-	(3.18)	(3.18)
Reversal of depreciation credited from Reserve and Surplus		(1.25)	(1.26)	(5.02)
Deferred Tax Assets		-	32.71	32.71
<b>Sub-Total</b>		<b>559.24</b>	<b>636.69</b>	<b>2,008.06</b>
<b>Other Comprehensive Income:</b>				
(A)	(i) Items that will not be reclassified subsequently to Profit or Loss:			
	(a) Remeasurements of the defined benefit plans	-	(141.52)	(141.52)
	(b) Equity Instruments through other comprehensive income	57.38	22.27	230.47
	<b>Sub-Total</b>	<b>57.38</b>	<b>(119.25)</b>	<b>88.95</b>
(B)	(i) Items that may be reclassified subsequently to Profit or Loss:			
	(a) Debt instruments through other comprehensive income	18.30	-	(23.30)
	(b) Income tax relating to items that may be reclassified to Profit or Loss	(6.33)	-	8.06
	<b>Sub-Total</b>	<b>11.97</b>	<b>-</b>	<b>(15.24)</b>
<b>Total Comprehensive Income for the period</b>		<b>628.59</b>	<b>517.44</b>	<b>2,081.77</b>

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN  
EXECUTIVE VICE CHAIRMAN

Place: Chennai  
Date: August 04, 2017





---

**TTK Healthcare**  
**LIMITED**

---

TTKH:SECL:GJ:154:17

August 04, 2017

National Stock Exchange of India Limited (NSE)  
Exchange Plaza  
Bandra Kurla Complex  
Bandra East  
Mumbai 400 051

---

Scrip Code : TTKHLTCARE

---

Dear Sirs,

**Re : Limited Review – Auditors' Report**

We are forwarding herewith a copy of Limited Review – Auditors' Report, in respect of the Unaudited Financial Results of the Company for the First Quarter ended 30<sup>th</sup> June, 2017, approved by the Board of Directors of the Company at their meeting held today.

Kindly take the above document on record.

Thanking you

Yours faithfully  
For TTK Healthcare Limited

**(S KALYANARAMAN)**  
*Director & Wholetime Secretary*

Encl. : a/a

**INDEPENDENT AUDITORS' LIMITED REVIEW REPORT**  
**For the Quarter ended 30<sup>th</sup> JUNE, 2017**

To

**The Board of Directors**  
**TTK Healthcare Limited**  
**No.6, Cathedral Road**  
**Chennai 600 086**

- (1) We have reviewed the accompanying Statement of Unaudited Financial Results ('the Statement') of TTK Healthcare Limited ('the Company') for the Quarter ended 30<sup>th</sup> June, 2017, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ["the SEBI (LODR) Regulations, 2015"] as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

- (2) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- (3) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, including the manner in which it is to be disclosed or that it contains any material misstatement.

**For M/s Aiyar & Co.**  
**Chartered Accountants**  
**Firm Regn. No.000063S**

*N. Sridharan*

**N SRIDHARAN**  
**PROPRIETOR**  
**Membership No.20503**

**For M/s S Viswanathan LLP**  
**Chartered Accountants**  
**Firm Regn. No.004770S / S200025**

*C N Srinivasan*

**C N SRINIVASAN**  
**PARTNER**  
**Membership No.18205**

**Place : Chennai**  
**Date : August 04, 2017**

